An observational study in Acute Mesenteric Ischemia, sponsored by Aalborg University Hospital. Completed. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2022-12-29.
Sponsored by Aalborg University Hospital · Observational
To investigate a number of blood based parameters in patients with intestinal ischaemia compared to patients with other acute abdominal diseases.
Intestinal ischemia is a life-threatening condition defined by interrupted blood supply to the intestinal tissue. Primary and secondary ischemia is obstruction of blood-supply due to vascular and extra-vascular pathology, respectively.
Early diagnosis and treatment are critical to save the ischemic bowel. Clinical findings of secondary intestinal ischaemia are related to the underlying cause e.g. vomiting and palpable hernia. Abdominal computed tomography (CT) can effectively visualize the causes. In contrast, the diagnosis of primary intestinal ischemia is often delayed due to the absence of specific clinical findings. Primary intestinal ischemia is visualized with CT ateriography, revealing mesentery arterial obstruction. However, in the acute setting a non-arterial phase CT is often performed but the findings are unspecific in the early stages and the pattern of findings which could indicate primary ischemia are not well understood. In primary and secondary ischemia, standard blood-based parameters are inconsistently elevated and highly unspecific. Newer blood-based parameters such as D-lactate has been proposed as ischaemic markers. D-lactate is produced by bacteria in the bowel lumen and translocation through a damaged bowel wall makes it a potential marker of intestinal ischemia.
A case-control-study of all acute admitted patients with abdominal pain in Aalborg, Denmark in the mentioned time range. The sensitivity and specificity of potiential biomarkers in a blood sample at time of admission as a marker of intestinal ischaemia will be examined.
40 studies on the registry are indexed under Mesenteric Ischemia; 14 are open to participants now.
This study's enrollment of 2,958 is above the median of 154 across 26 observational studies indexed under Mesenteric Ischemia.
Browse Mesenteric Ischemia studies →Aalborg University Hospital is the lead sponsor of 198 studies on the registry; 41 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Referred patient from the whole uptake area whic is 590.000 inhabitans for regional hospital functions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Surgical verified AIN patients. A blood sample is drawn just after inclusion and stored for later analysis.
Diagnostic Test: Blood sample analysis
Non-AIN patients. A blood sample is drawn just after inclusion and stored for later analysis.
Diagnostic Test: Blood sample analysis
Analysis of proposed biomarkers.
D-lactate
Measurement of baseline level of D-lactate as a predictor of AIN
Time frame: 2015-2019, Just after inclusion
I-FABP
Measurement of baseline level of I-FABP as a predictor of AIN.
Time frame: 2015-2019, Just after inclusion
Endothelin-1
Measurement of baseline level of Endothelin-1 as a predictor of AIN
Time frame: 2015-2019, Just after inclusion
L-lactate
Measurement of baseline level of L-lactate as a predictor of AIN
Time frame: 2015-2019, Just after inclusion
No study locations are listed for this record.
Plan to share: No
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.